MiR-29 mimics inhibited TGF-β activation and reduced fibrosis, while ASO and nanoparticle strategies aimed at increasing miR-29 expression have shown efficacy in DKD models [67,68]. Here, TGFB1 is linked to diabetic kidney disease.